Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
PaxMedica, Inc. (PXMD)
NASDAQ:PXMD
PaxMedica, Inc. (PXMD) Stock Price & Analysis
57 Followers
PXMD Stock Chart & Stats
Day’s Range$0.55 - $0.77
52-Week Range― - ―
Previous Close$0.74
Volume3.89M
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 13, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,408,067
10 Day Avg. Volume12,871,728
30 Day Avg. Volume4,587,551
Standard Deviation0.23
R-Squared0.02
Alpha-0.19
Financial Highlights & Ratios
Price to Book (P/B)1.84
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
PaxMedica, Inc. News
PremiumCompany Announcements
PaxMedica Releases Updated Investor Presentation Online
PremiumCompany Announcements
PaxMedica Accelerates RSU Vesting for Top ExecutivesRisk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PXMD FAQ
What was PaxMedica, Inc.’s price range in the past 12 months?
Currently, no data Available
What is PaxMedica, Inc.’s market cap?
Currently, no data Available
When is PaxMedica, Inc.’s upcoming earnings report date?
PaxMedica, Inc.’s upcoming earnings report date is May 13, 2024 which is in 23 days.
How were PaxMedica, Inc.’s earnings last quarter?
PaxMedica, Inc. released its earnings results on Mar 27, 2024. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$0.88 by $0.08.
Is PaxMedica, Inc. overvalued?
According to Wall Street analysts PaxMedica, Inc.’s price is currently Overvalued.
Does PaxMedica, Inc. pay dividends?
PaxMedica, Inc. does not currently pay dividends.
What is PaxMedica, Inc.’s EPS estimate?
PaxMedica, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PaxMedica, Inc. have?
Currently, no data Available
What happened to PaxMedica, Inc.’s price movement after its last earnings report?
PaxMedica, Inc. reported an EPS of -$0.8 in its last earnings report, beating expectations of -$0.88. Following the earnings report the stock price went up 5.882%.
Which hedge fund is a major shareholder of PaxMedica, Inc.?
Currently, no hedge funds are holding shares in PXMD
---
PaxMedica, Inc. Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
PXMD Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 23.2%
Last 30 Days ▲ 13.4%
Last 30 Days ▲ 13.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-97.78%
12-Months-Change
Fundamentals
Return on Equity
-1046.96%
Trailing 12-Months
Asset Growth
157.69%
Trailing 12-Months
Company Description
PaxMedica, Inc.
PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes.
---
PXMD Stock 12 Months Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering PXMD
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-0.40%
initiated a buy rating 5 months ago
Copying Boobalan Pachaiyappan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -0.40% per trade.
---